Yesterday I closed the approval post with a line I meant literally: “Amgen’s Imlygic proved a virus could get approved; the harder question is whether one can sell. That question starts now.”
Today the 8-K landed with Exhibit 99.2 — the full TUDRIQEV approval-call deck — and it is the first real look at how management intends to answer that question. The stock fell -6.2%, from $12.86 to $12.06, on the day the launch plan became public. That’s the reaction worth decoding.
The Receipts
The launch is deliberately narrow, not a land grab. The deck lays out a three-phase account strategy: ~200 early-adopter accounts in the first ~6 months, ~450 accounts over the next 9–12 months, ~1,200 accounts longer-term. The implication: this is a targeted specialty launch, not a broad oncology push. Concentrating on ~200 sites is the correct move for a therapy that needs an interventional radiologist in the room, but it also caps how fast the revenue line can inflect. Anyone modeling a hockey stick off the ~10,000-patient addressable TAM in the first four quarters is modeling the wrong shape.
They did the account homework before approval. Across those ~200 early-adopter accounts, Replimune reports 94% have an identified medical-oncology champion and 87% have an identified interventional-radiology (IR) champion, with “significant proactive requests for engagement immediately following approval.” Why it matters: the friction I named in February — the oncologist/IR coordination problem that made me put Commercial Viability at Low/Medium — is exactly what those two percentages are meant to address. Having a named IR at 87% of target sites is the single most encouraging operational number in the deck, because the IR is the bottleneck, not the oncologist.
Product ships in ~60 days. Not same-week. The deck says TUDRIQEV is “expected to ship in approximately 60 days,” which puts first commercial doses in early October and means Q3 revenue will be a rounding error. First revenue reporting is listed as a next-6-months milestone, not a next-quarter one.
Payer groundwork covers ~80% of lives, and existing procedural codes are in place. Replimune says payer engagement has reached “nearly 80% of covered lives,” and that existing procedural codes already support injections billed by IRs and medical oncologists. The implication: no new J-code fight, no waiting on CMS to invent a billing pathway. For an intratumoral product, that’s a genuinely meaningful de-risking of the access ramp — this is the plumbing that sinks logistically heavy launches.
Price is not disclosed. The deck says only that cost of treatment is “in line with comparable treatments in advanced melanoma.” That’s a placeholder, not a number. In a setting where the approved competitor is lifileucel (AMTAGVI) — a one-time cell therapy priced in the mid-six figures — “comparable” spans a very wide range for a drug dosed every 2 weeks for up to 8 cycles plus retreatment at physician discretion. Until there’s a WAC, the revenue model has a free variable in it.
Biosafety Level 1 and no reported transmission to close contacts. The label carries a warning on accidental exposure, but the deck confirms BSL-1 handling — the lowest level — with standard cleaning procedures and outpatient administration. Why it matters: a live herpes virus that required negative-pressure rooms would have been a launch-killer for community oncology. It doesn’t.
IGNYTE-3 enrollment is “on track.” The confirmatory trial is unchanged: ~400 patients, randomized 1:1, RP1 + nivolumab vs. treatment of physician’s choice (Opdualag, chemo, or PD-1 rechallenge), primary analysis overall survival. Interim OS still sits in 2H 2027.
State Street filed a 5.3% 13G. 4,440,144 shares, event date 06/30/2026, filed as a parent holding company. This is index/passive money, not a conviction signal — but it does mean the shareholder register now includes a large passive holder alongside the 25,103,489-share (25.94%) Baker Bros resale shelf that went effective July 29.
Decoding the -6.2%
Three things, none of which are about the science.
